StocksMedium•6 October 2026•
1 min read
Vaxcyte Announces $1 Billion Capital Raise via Equity and Convertible Notes
Key Facts
1Vaxcyte announced a public offering of $500 million in common stock and pre-funded warrants.
2The company plans to issue $500 million in aggregate principal amount of convertible senior notes due 2032.
3Proceeds will be used to fund VAX-31 vaccine clinical programs and commercial preparations for its U.S. launch.
Vaxcyte announced a public offering of $500 million in common stock and pre-funded warrants, according to Investing News Network. The company also plans to issue an additional $500 million in aggregate principal amount of convertible senior notes due 2032, bringing the total capital raise to $1 billion.
PCVX closed at $73.82 on October 5, 2026, after trading between a day low of $71.6 and a high of $90.75. The company intends to use the proceeds to fund the clinical development of its VAX-31 vaccine and scale up manufacturing preparations for its anticipated U.S. market entry.